Genomic profiles of glioma

Current Neurology and Neuroscience Reports

Volumn 11, Issue 3, 2011, Pages 291-297

  Brennan, Cameron ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Glioblastoma; Glioma; IDH; Molecular subclassification; TCGA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CDKN2A GENE; CELL PROLIFERATION; DIAGNOSTIC VALUE; EARLY CANCER; EGFR GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENOME ANALYSIS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; NEUROPATHOLOGY; ONCOGENE; PRIMARY TUMOR; PROGNOSIS; SEQUENCE ANALYSIS; TRANSCRIPTOMICS; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; CLASSIFICATION; GENETICS; GLIOMA; HUMAN GENOME; PATHOLOGY; REVIEW; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; GENOME, HUMAN; GLIOBLASTOMA; GLIOMA; HUMANS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 79961140711     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0198-7     Document Type: Article

References (46)

1. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-8.
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-12.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
4. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319-31.
5. Jaeckle KA, Decker PA, Ballman KV, et al. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. Journal of neuro-oncology. Dec 12 2010.
6. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-710. (Pubitemid 350070717)
7. Attolini CS, Cheng YK, Beroukhim R, et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci USA. 2010;107(41):17604-9.
8. Caskey L, Wang R, Bruner J, Yung W, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Research. Jan 1 1999.
9. Fuller GN, Hess KR, Rhee C, et al. Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology-Based Classification, Correlates with Survival, and Reveals Clinically-Relevant Novel Glioma Subsets. Brain Pathol. 2002;12:108-16. (Pubitemid 33131367)
10. Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002;1:1229-36.
11. Rickman D, Bobek M, Misek D, Kuick R, Blaivas M. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Research. Jan 1 2001.
12. Sallinen S, Sallinen P, Haapasalo H, Helin H. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Research. Jan 1 2000.
13. Shai R, Shi T, Kremen T, Horvath S, Liau L. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003;22:4918-23. (Pubitemid 36981282)
14. Somasundaram K, Reddy SP, Vinnakota K, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene. 2005;24(47):7073-83. (Pubitemid 41573636)
15. Tanwar M, Gilbert M, Holland E. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Research. Jan 1 2002.
16. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-73. (Pubitemid 43357943)
17. Freije W, Castro-Vargas F, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64(18):6503.
18. Nigro J, Misra A, Zhang L, Smirnov I, Colman H. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Research. Jan 1 2005.
19. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
20. Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations. PLoS ONE. 2009;4 (11):1-10.
21. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1(4):304-13.
22. Guo Y, Xiao P, Lei S, et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai). 2008;40 (5):426-36. (Pubitemid 351704046)
23. Huse J, Phillips H, Brennan C. Molecular Subclassification of Diffuse Gliomas: Seeing Order in the Chaos. Glia. 2011;in press.
24. Paugh BS, Qu C, Jones C, et al. Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. J Clin Oncol. 2010;28(18):3061-8.
25. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462 (7274):739-744.
26. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+?dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4):487-94.
27. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597-602.
28. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
29. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-74.
30. Labussiere M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74 (23):1886-90.
31. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16(9):387-97.
32. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
33. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-67.
34. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-50.
35. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
36. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in lowgrade gliomas. Neurology. 2010;75(17):1560-6.
37. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-604.
38. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-54.
39. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118(5):599-601.
40. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun. 2009;390(3):547-51.
41. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol. 2010;119(4):509-11.
42. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
43. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39-51.
44. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-7.
45. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22 (6):633-8.
46. Allingham-Hawkins D, Lea A, Levine S. DecisionDx-GBM gene expression assay for prognostic testing in glioblastoma multiform. PLoS Curr. 2010;2:RRN1186.